Each tumour has a different genetic makeup, which makes it react to therapies very differently. By analysing and monitoring the presence of genetic sequences in a tumour, patients can be prescribed more targeted treatment and screening.
Dr Jelena Aleksic, GeneAdviser’s CEO, commented: “Birmingham Women’s Hospital combines outstanding and comprehensive genetics research and clinical expertise, making it an internationally renowned clinical laboratory. We are delighted to make their excellent genetic testing more accessible to doctors worldwide, helping them provide better care for their patients.”
Professor Michael Griffiths, the Birmingham Women’s Hospital Genetics Laboratory Director, added: "We are excited to join forces with GeneAdviser to facilitate worldwide access to our genetic test portfolio. As the largest NHS genetics laboratory we already work closely with clinicians across the UK and internationally, and GeneAdviser will allow them to easily order the genetic tests they need for their patients, whilst streamlining administrative processes for our staff."
Their partnership also expands beyond solid tumour sequencing, bringing forward a selection of high quality genetic tests in oncology and other medical specialties. Other tests from Birmingham Women’s Hospital include their Lucina NIPT (non invasive prenatal testing), a highly accurate genetic prenatal testing that screens for trisomies such as Down syndrome using a single maternal blood sample.